Abstract :
[en] Coronary disease risk increases inversely with high-d. lipoprotein (HDL) level. The measurement of the biodistribution
and clearance of HDL in vivo, however, has posed a tech. challenge. This study presents an approach to the
development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective
cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney,
the sites of HDL catabolism, whereas the std. MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acidbismethylamide
(GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI
to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metab. and regulation in
vivo.
Scopus citations®
without self-citations
8